XPS™ contract signed with leading hospital in Boston

The XPS™ is the first sold to New England, USA. Delivery and installation of the
XPS™ is estimated to take place early May 2016.
Boston’s Brigham and Women’s Hospital (BWH) is an international leader in many
areas of medicine and is a teaching hospital for Harvard Medical School. BWH has
a well-developed lung transplant program and with the investment in the Ex Vivo
Lung Perfusion (EVLP) technology and the XPS™ BWH will get the opportunity to
increase the lung transplant program and support more patients.

XPS™ is the only CE-marked and FDA approved (Humanitarian Device Exemptions
approval) integrated system on the market today which gives the user the
flexibility to perform evaluation of lungs before transplantation through a
standardized and simplified procedure. Use of XPS™ has shown good clinical
results at 18 clinics in the US, many of which are national leaders in their
field. Six XPS™ contracts have now been signed by European clinics, giving them
access to the XPS™ system for lung transplantation, and the company notes
continuing high interest for the XPS™ in the US and in Europe.

“We are delighted and proud that EVLP with XPS™ and STEEN Solution™ will be used
for evaluating lungs for transplantation at the very well reputed Brigham and
Women’s Hospital in Boston. This is one of only two hospitals performing lung
transplantation in all of the states in the North-East (New England) of the USA.
The company sees a continued high interest from American and European clinics to
set up XVIVOs XPS ™ system to facilitate lung evaluation with the aim of using
more of the donated lungs”, says Magnus Nilsson, CEO of XVIVO Perfusion.

April 15, 2016
Gothenburg
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +1 720 616 2101,
christoffer.rosenblad@xvivoperfusion.com
Magnus Nilsson, CEO, +46 31 788 2150, magnus.nilsson@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the
company’s website, www.xvivoperfusion.com

The information was submitted for publication onApril 15, 2016 at 8:30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB is a medical technology company which develops solutions and
systems for assessing and preserving organs outside the body and for selecting
usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the
USA. The XVIVO share is listed on NASDAQ First North premier and has the ticker
symbol XVIVO. More information can be found on the website
www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity
number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com